242 related articles for article (PubMed ID: 19676044)
1. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
Salnikov AV; Gladkich J; Moldenhauer G; Volm M; Mattern J; Herr I
Int J Cancer; 2010 Feb; 126(4):950-8. PubMed ID: 19676044
[TBL] [Abstract][Full Text] [Related]
2. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
3. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer.
Alamgeer M; Ganju V; Szczepny A; Russell PA; Prodanovic Z; Kumar B; Wainer Z; Brown T; Schneider-Kolsky M; Conron M; Wright G; Watkins DN
Thorax; 2013 Dec; 68(12):1095-104. PubMed ID: 23878161
[TBL] [Abstract][Full Text] [Related]
5. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
[TBL] [Abstract][Full Text] [Related]
6. CD133 expression: a potential prognostic marker for non-small cell lung cancers.
Mizugaki H; Sakakibara-Konishi J; Kikuchi J; Moriya J; Hatanaka KC; Kikuchi E; Kinoshita I; Oizumi S; Dosaka-Akita H; Matsuno Y; Nishimura M
Int J Clin Oncol; 2014 Apr; 19(2):254-9. PubMed ID: 23479121
[TBL] [Abstract][Full Text] [Related]
7. Lack of prognostic significance of neuroendocrine differentiation and stem cell antigen co-expression in resected early-stage non-small cell lung cancer.
Gottschling S; Jensen K; Herth FJ; Thomas M; Schnabel PA; Herpel E
Anticancer Res; 2013 Mar; 33(3):981-90. PubMed ID: 23482770
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer.
Tu Z; Xie S; Xiong M; Liu Y; Yang X; Tembo KM; Huang J; Hu W; Huang X; Pan S; Liu P; Altaf E; Kang G; Xiong J; Zhang Q
Int J Oncol; 2017 Feb; 50(2):505-514. PubMed ID: 28000861
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysis.
Wang W; Chen Y; Deng J; Zhou J; Zhou Y; Wang S; Zhou J
Tumour Biol; 2014 Oct; 35(10):9769-75. PubMed ID: 24973892
[TBL] [Abstract][Full Text] [Related]
10. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas.
Li F; Zeng H; Ying K
Med Oncol; 2011 Dec; 28(4):1458-62. PubMed ID: 20717756
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy.
Shien K; Toyooka S; Ichimura K; Soh J; Furukawa M; Maki Y; Muraoka T; Tanaka N; Ueno T; Asano H; Tsukuda K; Yamane M; Oto T; Kiura K; Miyoshi S
Lung Cancer; 2012 Jul; 77(1):162-7. PubMed ID: 22387005
[TBL] [Abstract][Full Text] [Related]
12. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer.
Tirino V; Camerlingo R; Franco R; Malanga D; La Rocca A; Viglietto G; Rocco G; Pirozzi G
Eur J Cardiothorac Surg; 2009 Sep; 36(3):446-53. PubMed ID: 19464919
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological significance of stem-like CD133(+)CXCR4(+) cells in esophageal squamous cell carcinoma.
Lu C; Xu F; Gu J; Yuan Y; Zhao G; Yu X; Ge D
J Thorac Cardiovasc Surg; 2015 Aug; 150(2):386-95. PubMed ID: 26092504
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of PROM1 (CD133) confers poor prognosis in non-small cell lung cancer.
Qiu ZX; Zhao S; Mo XM; Li WM
Int J Clin Exp Pathol; 2015; 8(6):6589-95. PubMed ID: 26261540
[TBL] [Abstract][Full Text] [Related]
15. Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis.
Wu H; Qi XW; Yan GN; Zhang QB; Xu C; Bian XW
PLoS One; 2014; 9(6):e100168. PubMed ID: 24940615
[TBL] [Abstract][Full Text] [Related]
16. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.
Pallini R; Ricci-Vitiani L; Banna GL; Signore M; Lombardi D; Todaro M; Stassi G; Martini M; Maira G; Larocca LM; De Maria R
Clin Cancer Res; 2008 Dec; 14(24):8205-12. PubMed ID: 19088037
[TBL] [Abstract][Full Text] [Related]
17. Putative stem cell markers in non-small-cell lung cancer: a clinicopathologic characterization.
Sterlacci W; Savic S; Fiegl M; Obermann E; Tzankov A
J Thorac Oncol; 2014 Jan; 9(1):41-9. PubMed ID: 24346092
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review.
Qu H; Li R; Liu Z; Zhang J; Luo R
Int J Clin Exp Pathol; 2013; 6(11):2644-50. PubMed ID: 24228135
[TBL] [Abstract][Full Text] [Related]
19. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
[TBL] [Abstract][Full Text] [Related]
20. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.
Shin JH; Lee YS; Hong YK; Kang CS
J Neurooncol; 2013 Dec; 115(3):333-41. PubMed ID: 24129546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]